OS Therapies Inc (OSTX): Entry into a Material Definitive Agreement
OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ea030301901ex1-1.htm OPEN MARKET SALE AGREEMENTSM, DATED AUGUST 21, 2026, BY AND BETWEEN OS THERAPIES INCORPORATED AND JEFFERIES LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENT SM August 21, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen:
How this was made
The 30-second read
Why it matters
The open market sale program provides a flexible mechanism to raise up to a material amount of cash, potentially supporting upcoming trial expenses.
Market read
A new equity‑raising mechanism for a micro‑cap biotech; may affect share supply and price.
What to watch
The floor price of $1.00 is low; market may view the raise as a sign of cash need.
Background
OS Therapies is a clinical‑stage biotech developing therapies for rare diseases. The company previously raised capital via private placements.
Ticker impact
OS Therapies filed an 8‑K announcing an Open Market Sale Agreement with Jefferies to issue and sell common shares under a shelf registration.
Short‑term pressure on the stock price as shares may be sold; long‑term upside if capital is deployed effectively.
The agreement authorizes future share sales at a floor price of $1.00, indicating a planned equity raise that could affect supply‑demand dynamics.
Market effects
May signal increased financing activity in the biotech/clinical‑stage sector.
Limited to U.S. markets where the shares are listed.
Low, as the filing concerns a micro‑cap biotech.
Counterpoint
If the company fails to deploy proceeds efficiently, the dilution could outweigh benefits.
Key entities
- companyOS Therapies Inc
Biotech issuer filing the 8‑K.
- agentJefferies LLC
Sales agent for the open market sale program.
